NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-methyl-1,2-bis(pyridin-3-yl)propan-1-one
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Metapirone
|
Metapyron
|
Metapyrone
|
Metopiron
|
Metopyrone
|
Metopirone
|
|
|
Synonyms
|
2-Methyl-1,2-di-3-pyridyl-1-propanone
|
Metyrapone
|
Su-4885
|
Metyrapone
|
2-Methyl-1,2-di-3-pyridyl-1-propanone
|
Methapyrapone
|
Mepyrapone
|
Methbipyranone
|
Methopirapone
|
Methopyrapone
|
Methopyrinine
|
Methopyrone
|
Metyrapon
|
Metroprione
|
Metyrapone
|
2-Methyl-1,2-di-3-pyridyl-1-propanone
|
2-甲基-1,2-二-3-吡啶基-1-丙酮
|
美替拉酮
|
2-甲基-1,2-二-3-吡啶基-1-丙酮
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
Beilstein Number
|
|
PubChem SID
|
|
PubChem CID
|
|
CHEBI ID
|
|
ATC CODE
|
|
CHEMBL
|
|
Chemspider ID
|
|
DrugBank ID
|
|
KEGG ID
|
|
Unique Ingredient Identifier
|
|
Wikipedia Title
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
H Acceptors
|
3
|
H Donor
|
0
|
LogD (pH = 5.5)
|
1.9471339
|
LogD (pH = 7.4)
|
2.0277522
|
Log P
|
2.028889
|
Molar Refractivity
|
65.9444 cm3
|
Polarizability
|
25.544344 Å3
|
Polar Surface Area
|
42.85 Å2
|
Rotatable Bonds
|
3
|
Lipinski's Rule of Five
|
true
|
Log P
|
2.09
|
LOG S
|
-2.72
|
Solubility (Water)
|
4.27e-01 g/l
|
DETAILS
DETAILS
DrugBank
Wikipedia
Sigma Aldrich
DrugBank -
DB01011
|
Item |
Information |
Drug Groups
|
approved |
Description
|
An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome. [PubChem] |
Indication |
Used as a diagnostic drug for testing hypothalamic-pituitary ACTH function. Occasionally used in Cushing's syndrome. |
Pharmacology |
Metopirone is an inhibitor of endogenous adrenal corticosteroid synthesis. |
Toxicity |
Oral LD50 in rats is 521 mg/kg. One case has been recorded in which a 6-year-old girl died after two doses of Metopirone, 2 g. Symptoms of overdose include cardiac arrhythmias, hypotension, dehydration, anxiety, confusion, weakness, impairment of consciousness, nausea, vomiting, epigastric pain, and diarrhea. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Hepatic. The major biotransformation is reduction of the ketone to metyrapol, an active alcohol metabolite. Metyrapone and metyrapol are both conjugated with glucuronide. |
Absorption |
Absorbed rapidly and well when administered orally. Peak plasma concentrations are usually reached 1 hour after administration. |
Half Life |
1.9 ±0.7 hours. |
Elimination |
After administration of 4.5 g metyrapone (750 mg every 4 hours), an average of 5.3% of the dose was excreted in the urine in the form of metyrapone (9.2% free and 90.8% as glucuronide) and 38.5% in the form of metyrapol (8.1% free and 91.9% as glucuronide) within 72 hours after the first dose was given. |
External Links |
|
|
Sigma Aldrich -
M2696
|
Biochem/physiol Actions Metyrapone is a glucocorticoid synthesis inhibitor; a standard in assessing adrenal gland function especially in response to stress, as well as pituitary gland function. In addition to acting as a glucocorticoid synthesis inhibitor, Metyrapone also inhibits cytochrome P450-mediated prostaglandin ω/ω-1 hydroxylase activity and impairs learning and memory. Data shows results in activation of the sleep EEG and a robust decrease in quantitative delta sleep. |
Sigma Aldrich -
856525
|
Packaging 1 g in glass bottle 250 mg in glass bottle |
PATENTS
PATENTS
PubChem Patent
Google Patent